According to a new report by UnivDatos Market Insights, The GLP-1 Analogues Market was valued at USD 37 Billion in 2023 and is expected to grow at a CAGR of 28% during the forecast period (2024-2032). This is mainly due to the increase in the global prevalence of type 2 diabetes and obesity, the growing need for weight management solutions, and the broadening of cardiovascular efficacy profile. The availability of new methods of drug delivery, especially including oral preparations and the development of long-acting analogues also increases the adoption of the drug. Furthermore, increased patient awareness levels and government promotion related to diabetes improve market access.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=69030

On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.

Segments that transform the industry

·        Based on application, the market is segmented into type 2 diabetes and weight loss. Type 2 diabetes held a significant share of the market in 2023. The increasing global incidence of type 2 diabetes leads to the need for more GLP-1 analogues such as liraglutide that help to manage blood sugar levels while promoting weight loss. Such drugs are progressively preferred with respect to conventional treatments for their multiple valued aspects. Moreover, companies are improving access by expanding into growth lots and partnering with healthcare facilities exerting pressure for early detection.

According to the report, the impact of GLP-1 Analogues has been identified to be high for the Asia-Pacific area.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=69030

Browse Related Reports:

·        Antibiotic Resistance Market

·        Software as a Medical Device Market

·        Opioid Use Disorder (OUD) Treatment Market

·        Sperm Bank Market

·        Deep Vein Thrombosis Market

·        Chronic Obstructive Pulmonary Disease Market

Some of how this impact has been felt include:

Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is because of a growing incidence of diabetes, the growth of cities, and, lastly, the increase in health care costs. Adding to this, the increased concerns among people regarding proper diabetes management drive the growth of superior diabetes management solutions in key areas such as China, India, and Japan. Moreover, companies pay much attention to growing the coverage through mergers, acquisitions, joint ventures, and own production facilities as well as localized advertisement techniques. More importantly, the approval of regulators and the availability of low-cost products are essential for new markets. Further, the concerned e-health technologies and telemedicine are helping the healthcare unit inpatient reach and compliance in rural areas.